Showing 1141-1150 of 20877 results for "".
- Dr. Kevin Pinski Presents Injectable Pearls at Noahhttps://reachmd.com/news/dr-kevin-pinski-presents-injectable-pearls-at-noah/2486902/At the 67th Noah Worcester Dermatological Society Annual Meeting, Kevin Pinski, MD, presented “Injectable Pearls,” drawing on nearly 4 decades of experience with neuromodulators, fillers, and cosmetic injectables. The presentation covered practical techniques, pati
- Analysis: PRS Improves Melanoma Risk Predictionhttps://reachmd.com/news/tildrakizumab-matches-risankizumab-guselkumab-in-mid-term-psoriasis-outcomes/2486903/A polygenic risk score (PRS) improved prediction of invasive cutaneous melanoma when added to an established clinical risk model, according to findings from a recent genome-wide association analysis. The PRS was derived from a
- Hepatic Arterial Infusion Oxaliplatin After Colorectal Liver Metastasis Resectionhttps://reachmd.com/news/hepatic-arterial-infusion-oxaliplatin-after-colorectal-liver-metastasis-resection/2486884/Key Takeaways Longer hepatic recurrence-free survival was observed with HAI oxaliplatin plus IV LV5FU2 than with IV oxaliplatin plus IV LV5FU2 after surgery for four or more colorectal liver metastases. Recurrence-free survival also favored HAI, while
- Fecal Microbiota Transplant Did Not Improve MDRO Decolonizationhttps://reachmd.com/news/fecal-microbiota-transplant-mdro-decolonization/2486885/Key Takeaways No significant difference in 4-week MDRO decolonization was observed between FMT and sham. Reductions in AMR genes also did not differ significantly, and adverse events were similar across groups. FMT increased bacterial diversit
- Intra-Arterial Alteplase After Thrombectomy in Basilar Occlusionhttps://reachmd.com/news/intra-arterial-alteplase-after-thrombectomy-in-basilar-occlusion/2486861/Key Takeaways Adjunct intra-arterial alteplase was not associated with better 90-day functional independence after successful thrombectomy for basilar artery occlusion. Symptomatic intracranial hemorrhage and 90-day mortality were similar between group
- Intrathecal Morphine 75 Mcg vs 100 Mcg for Cesarean Analgesiahttps://reachmd.com/news/intrathecal-morphine-75-mcg-vs-100-mcg-for-cesarean-analgesia/2486862/Key Takeaways The trial compared 75 mcg and 100 mcg intrathecal morphine during spinal anesthesia for cesarean delivery. Analgesic outcomes included postoperative pain, rescue analgesic use, and time to first analgesic request. Common opioid-r
- Workflow Redesign Improved Weight Care in Primary Care Trialhttps://reachmd.com/news/workflow-redesign-improved-weight-care-in-primary-care-trial/2486863/Key Takeaways PATHWEIGH was associated with a modest population-level change in weight trajectory during routine primary care. The intervention phase was linked to more discernable weight-related care and larger weight reductions among patients who rec
- Randomized Trial Tests Platelet Rich Plasma for Grade 2 Hamstring Injurieshttps://reachmd.com/news/randomized-trial-tests-platelet-rich-plasma-for-grade-2-hamstring-injuries/2486851/Key Takeaways This randomized trial compared platelet rich plasma with standard therapy alone in grade 2 hamstring muscle injuries. Reported outcome domains included the recovery course, return to play or return to sport, pain-related measures, radiolo
- Incyte Reports Positive Vitiligo Phase 3 Data Supporting JAK Therapieshttps://reachmd.com/news/incyte-reports-positive-vitiligo-phase-3-data-supporting-jak-pipeline/2486888/Incyte provided updated data on two therapies in its dermatology pipeline during its recent earnings call, according to a statement from the company. Ruxolitinib Update
- Skill-Based Virtual Reality Therapy Shows Durable Benefit in High-Impact Chronic Painhttps://reachmd.com/news/skill-based-virtual-reality-therapy-shows-durable-benefit-in-high-impact-chronic-pain/2486827/Key Takeaways At 2 years, larger improvements in pain interference, pain intensity, sleep disturbance, and disability were observed in high-impact chronic pain, while depression was not statistically different. At 2 years, 71.1% of participants with hi